COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes progressively difficult. The most common forms of COPD are chronic bronchitis and emphysema, and many patients suffer from a combination of the two diseases.
COPD is the fourth leading cause of death in America, behind heart disease, cancer, and stroke. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms but are undiagnosed.
Advancements Offered by Nebulization
Perforomist Inhalation Solution is a long-acting bronchodilator that is taken by nebulizer. Of the three types of devices used to deliver bronchodilators -- nebulizers, metered-dose inhalers, and dry powder inhalers -- nebulizers require no special technique or coordination, as the liquid medication is converted into a fine mist that patients inhale through a mouthpiece or face-mask while breathing naturally. Since nebulization is an easy, effective, and thorough method of delivering medication directly into the lungs, many COPD patients ask for it, particularly as their symptoms worsen.
Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and
efficient aerosol delivery systems for patients with asthma, chronic lung
disease, and cystic fibrosis. PARI's worldwide vision is to improve the
lives of those affected by respiratory diseases and those who care for
them. Maker of the world's leading breath-enhanced reusable nebulizer, the
PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also
manufactures the award-w
|SOURCE PARI Respiratory Equipment, Inc.|
Copyright©2007 PR Newswire.
All rights reserved